2026-W46 · Nov 9–Nov 15 · Company · Profile · published
STERIS company profile · infection prevention & procedural products: Healthcare, AST & Life Sciences · history · financial snapshot · S&P 500 rank #381 · STERIS公司業務歷史財務與標普500地位
SNAPSHOT
| Ticker | STE (NYSE) |
| Company | STERIS plc |
| GICS sector / industry | Health Care / Health Care Equipment |
| S&P 500 rank (by weight) | #381 · 0.03% (Nov 3, 2026) |
| Sector rank (by S&P 500 weight) | #47 in Health Care (Nov 3, 2026) |
| Headquarters | Mentor, Ohio (operational HQ; incorporated in Ireland) |
| Founded | 1985 |
| CEO | Daniel A. Carestio |
| Market cap | $22.56B (Nov 3, 2026) |
| SEC filings | EDGAR — CIK 0001757898 |
WHAT IT DOES
STERIS is a global provider of products and services that support patient care with an emphasis on infection prevention: consumables such as detergents and barrier products, services including equipment maintenance, instrument repair and outsourced reprocessing, capital equipment such as sterilizers and surgical tables, and operating-room connectivity. It reports three segments — Healthcare, Applied Sterilization Technologies (AST) and Life Sciences — after divesting its Dental segment in fiscal 2025, which is now shown as discontinued operations.
Revenues from continuing operations were $5,935.9M in fiscal 2026, up 8.7% on fiscal 2025, with constant-currency organic growth of 7.3%. Healthcare, at $4,208.6M, supplied 70.9% of revenues and grew 8.5% on service (+11.8%), consumable (+7.2%) and capital (+5.7%) growth; AST grew 9.6% to $1,138.5M on pricing and volume despite a sharp fall in capital-equipment sales, and Life Sciences grew 8.6% to $588.8M.
Segment operating income before adjustments was $1,381.9M, but reported income from operations was $1,101.8M after $265.0M of acquired-intangible amortisation and other adjustments. Net income attributable to shareholders was $782.3M, with diluted EPS from continuing operations of $7.93. Healthcare’s segment margin slipped to 24.6% from 25.0% as tariffs and inflation more than offset volume, pricing and productivity gains.
REVENUES BY SEGMENT — FISCAL 2026
| Segment | Revenues | Share | YoY |
|---|---|---|---|
| Healthcare | $4,208.6M | 70.9% | +8.5% |
| Applied Sterilization Technologies (AST) | $1,138.5M | 19.2% | +9.6% |
| Life Sciences | $588.8M | 9.9% | +8.6% |
| Total revenues | $5,935.9M | 100% | +8.7% |
HISTORY
| Year | Milestone |
|---|---|
| 1985 | Innovative Medical Technologies founded in Mentor, Ohio, by microbiologist Raymond Kralovic |
| 1987 | Renamed STERIS Corporation; Bill Sanford becomes first president and CEO |
| 1998 | Moves to the New York Stock Exchange under the ticker STE |
| 2015 | Acquires Synergy Health and becomes STERIS plc |
| 2021 | Acquires Cantel Medical, expanding infection prevention in endoscopy and life sciences; Dan Carestio becomes president and CEO |
| 2025 | Divests the Dental segment, presented thereafter as discontinued operations |
COMPETITIVE POSITION
FINANCIAL SNAPSHOT — FISCAL 2026
| Revenues (continuing operations) | $5,935.9M (+8.7% YoY) |
| Income from operations | $1,101.8M (vs $866.6M in fiscal 2025) |
| Income from operations before adjustments | $1,381.9M (vs $1,267.5M in fiscal 2025) |
| Net income attributable to shareholders | $782.3M (vs $614.6M in fiscal 2025) |
| Diluted EPS from continuing operations | $7.93 |
| Free cash flow | $982.9M (vs $787.2M in fiscal 2025) |
KEY RISKS
WHY IT MATTERS FOR THE S&P 500
STERIS is the S&P 500’s infection-prevention pure play at a 0.03% weight: the index’s exposure to hospital sterile processing and medical-device sterilization, a business that grows with procedure volumes rather than with drug prices or device launches.
Its Healthcare service growth and AST margins make it a quiet compounder inside Health Care, distinct from the drug and device makers that dominate the sector.
SOURCES & METHODOLOGY
| Market data | Slickcharts S&P 500 by weight (rank, weight, price — Nov 3, 2026 crawl) · StockAnalysis (market cap — Nov 3, 2026 crawl, single source) |
| Financials | STERIS fiscal 2026 Form 10-K (SEC EDGAR, filed May 2026; fiscal year ended Mar 31, 2026) |
| Sector classification | GICS via the List of S&P 500 companies (Wikipedia) |
| Library data | SPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information. |
Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com
FINANCIALS
公司快照
| 股票代號 | STE(NYSE) |
| 公司 | STERIS plc |
| GICS 板塊/行業 | 醫療保健/Health Care Equipment |
| 標普500排名(按權重) | 第381名 · 0.03%(2026 年 11 月 3 日) |
| 板塊內排名(按標普500權重) | 醫療保健第47名(2026 年 11 月 3 日) |
| 總部 | 美國俄亥俄州門托(營運總部;於愛爾蘭註冊) |
| 成立 | 1985年 |
| 行政總裁 | Daniel A. Carestio |
| 市值 | $22.56B(2026 年 11 月 3 日) |
| SEC 文件 | EDGAR — CIK 0001757898 |
業務概覽
STERIS 是一家全球供應商,提供支援病人護理的產品與服務,重點在於感染預防:消耗品如清潔劑及屏障產品、服務包括設備維護、器械維修及外判再處理、資本設備如滅菌器及手術台,以及手術室連接方案。公司報告三個分部——醫療保健、應用滅菌技術(AST)及生命科學——於 2025 財政年度出售牙科分部後,該分部現列為已終止經營業務。
2026 財政年度持續經營業務收入為 $5,935.9M,較 2025 財政年度增長 8.7%,按固定匯率有機增長 7.3%。醫療保健分部收入 $4,208.6M,佔收入 70.9%,增長 8.5%,服務(+11.8%)、消耗品(+7.2%)及資本設備(+5.7%)皆增長;AST 增長 9.6% 至 $1,138.5M,受定價與銷量帶動,儘管資本設備銷售大跌;生命科學增長 8.6% 至 $588.8M。
調整前分部經營收入為 $1,381.9M,但報告經營收入為 $1,101.8M,扣除已收購無形資產攤銷 $265.0M 及其他調整後。歸屬於股東的淨收入為 $782.3M,持續經營業務攤薄每股盈利為 $7.93。醫療保健分部利潤率由 25.0% 微跌至 24.6%,因關稅與通脹抵銷了銷量、定價及生產力帶來的改善。
收入按分部 — 2026財政年度
| 板塊 | 收入 | 佔比 | 同比 |
|---|---|---|---|
| 醫療保健 | $4,208.6M | 70.9% | +8.5% |
| 應用滅菌技術(AST) | $1,138.5M | 19.2% | +9.6% |
| 生命科學 | $588.8M | 9.9% | +8.6% |
| 收入總額 | $5,935.9M | 100% | +8.7% |
歷史沿革
| 年份 | 里程碑 |
|---|---|
| 1985年 | 微生物學家 Raymond Kralovic 於俄亥俄州門托創立 Innovative Medical Technologies |
| 1987年 | 更名為 STERIS Corporation;Bill Sanford 出任首任總裁兼行政總裁 |
| 1998年 | 轉往紐約證券交易所上市,代碼 STE |
| 2015年 | 收購 Synergy Health,成為 STERIS plc |
| 2021年 | 收購 Cantel Medical,擴展內窺鏡與生命科學感染預防業務;Dan Carestio 出任總裁兼行政總裁 |
| 2025年 | 出售牙科分部,其後列為已終止經營業務 |
競爭地位
財務快照 — 2026財政年度
| 收入(持續經營業務) | $5,935.9M(同比 +8.7%) |
| 經營收入 | $1,101.8M(2025 財政年度為 $866.6M) |
| 調整前經營收入 | $1,381.9M(2025 財政年度為 $1,267.5M) |
| 歸屬於股東的淨收入 | $782.3M(2025 財政年度為 $614.6M) |
| 持續經營業務攤薄每股盈利 | $7.93 |
| 自由現金流 | $982.9M(2025 財政年度為 $787.2M) |
主要風險
對標普500的重要性
STERIS 是標普500中感染預防的純粹代表,權重 0.03%:指數內醫院無菌處理與醫療器械滅菌的敞口,其業務隨手術量而非藥價或器械上市而增長。
其醫療保健服務增長與 AST 利潤率令其成為醫療保健板塊內低調的複合增長者,有別於主導板塊的藥廠與器械製造商。
來源與方法
| 市場數據 | Slickcharts 標普500權重榜(排名、權重、價格——2026 年 11 月 3 日抓取)· StockAnalysis(市值——2026 年 11 月 3 日抓取,單一來源) |
| 財務 | STERIS 2026 財政年度 Form 10-K(SEC EDGAR,2026 年 5 月提交;財政年度截至 2026 年 3 月 31 日) |
| 板塊分類 | GICS,據 S&P 500 公司清單(Wikipedia) |
| 圖庫數據 | SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。 |
來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com
財報
SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。
Entered 2026-11-03 17:55 · updated 2026-11-15 00:03 · rev 5